UY28577A1 - Proceso químico e intermedios - Google Patents

Proceso químico e intermedios

Info

Publication number
UY28577A1
UY28577A1 UY28577A UY28577A UY28577A1 UY 28577 A1 UY28577 A1 UY 28577A1 UY 28577 A UY28577 A UY 28577A UY 28577 A UY28577 A UY 28577A UY 28577 A1 UY28577 A1 UY 28577A1
Authority
UY
Uruguay
Prior art keywords
formula
calcium salt
chemical
intermediate process
pyrimidim
Prior art date
Application number
UY28577A
Other languages
English (en)
Inventor
Horbury John
Okada Tetsuo
Laffan David Dermot Patrock
Original Assignee
Astrazeneca Uk Ltd Y Shionogi
Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29595716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28577(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd Y Shionogi, Company Ltd filed Critical Astrazeneca Uk Ltd Y Shionogi
Publication of UY28577A1 publication Critical patent/UY28577A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un proceso para la fabricación de la sal de calcio de ácido (E) -7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidim-5-il) (3R, 5S)-3, 5-dihidroxihept-6-enoico, útil como un inhibidor de la HMG CoA reductasa, a partir de un compuesto de fórmula (7) en donde A es un grupo protector de acetal o cetal y R es alquilo, mediante compuestos cristalinos de fórmula (8) o de fórmula (10). También se describen intermedios cristalinos de las fórmulas 7,8 y 10.
UY28577A 2003-10-24 2004-10-22 Proceso químico e intermedios UY28577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0324791.3A GB0324791D0 (en) 2003-10-24 2003-10-24 Chemical process

Publications (1)

Publication Number Publication Date
UY28577A1 true UY28577A1 (es) 2005-06-30

Family

ID=29595716

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28577A UY28577A1 (es) 2003-10-24 2004-10-22 Proceso químico e intermedios

Country Status (29)

Country Link
US (2) US20070255060A1 (es)
EP (2) EP2272842A1 (es)
JP (3) JP2007509119A (es)
KR (1) KR20060132829A (es)
CN (2) CN101654453B (es)
AR (1) AR046191A1 (es)
AU (1) AU2004285750B2 (es)
BR (1) BRPI0415681A (es)
CA (1) CA2543358A1 (es)
CY (1) CY1114145T1 (es)
DK (1) DK1682536T3 (es)
ES (1) ES2404693T3 (es)
GB (1) GB0324791D0 (es)
HK (1) HK1092462A1 (es)
IL (1) IL175086A0 (es)
IS (1) IS8478A (es)
MY (1) MY146002A (es)
NO (1) NO20062263L (es)
NZ (1) NZ547094A (es)
PL (1) PL1682536T3 (es)
PT (1) PT1682536E (es)
RU (1) RU2372349C2 (es)
SA (1) SA04250425B1 (es)
SI (1) SI1682536T1 (es)
TW (1) TWI344957B (es)
UA (1) UA83076C2 (es)
UY (1) UY28577A1 (es)
WO (1) WO2005042522A1 (es)
ZA (1) ZA200603173B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
WO2003006439A1 (en) 2001-07-13 2003-01-23 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DK1578731T3 (da) 2002-12-16 2010-02-15 Astrazeneca Uk Ltd Fremgangsmåde til fremstilling af pyrimidinforbindelser
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
HU227120B1 (hu) * 2005-05-26 2010-07-28 Richter Gedeon Nyrt Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül
US9150518B2 (en) 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
ES2567171T3 (es) 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
US8318933B2 (en) * 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2008096257A1 (en) * 2007-02-08 2008-08-14 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
EP2178890A1 (en) * 2007-07-12 2010-04-28 Teva Pharmaceutical Industries Ltd. Purification of rosuvastatin intermediate by thin film evaporation and chemical method
EP2022784A1 (en) * 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
US8793497B2 (en) * 2008-05-09 2014-07-29 Qualcomm Incorporated Puzzle-based authentication between a token and verifiers
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
CA2749727A1 (en) 2009-01-15 2010-07-22 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
EP2467363A1 (en) * 2009-08-17 2012-06-27 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
EP2336116A1 (en) * 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN102219749B (zh) * 2010-04-14 2013-07-17 上海京新生物医药有限公司 一种制备瑞苏伐他汀钙的方法
US8536330B2 (en) 2010-04-23 2013-09-17 Ranbaxy Laboratories Limited Intermediates for the preparation of HMG-CoA reductase inhibitors
KR101292238B1 (ko) * 2010-07-01 2013-07-31 주식회사유한양행 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 그의 중간체의 제조방법
HU230987B1 (hu) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
CN103313983B (zh) * 2011-01-18 2016-06-29 中化帝斯曼制药有限公司荷兰公司 在碱存在下制备他汀类化合物的方法
CN103848790B (zh) * 2012-12-05 2016-08-03 安徽省庆云医药化工有限公司 瑞舒伐他汀酯的晶型及其制备方法
CN103724278B (zh) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 他汀类中间体及其衍生物的制备方法
CN113461619A (zh) 2014-02-06 2021-10-01 株式会社Api 瑞舒伐他汀钙及其中间体的生产方法
CN105153040B (zh) * 2015-10-15 2018-04-13 江苏师范大学 瑞舒伐他汀钙新晶型及其制备方法
CN105461636A (zh) * 2015-12-30 2016-04-06 安徽美诺华药物化学有限公司 一种瑞舒伐他汀甲酯的合成方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
KR900701778A (ko) 1988-10-06 1990-12-04 예안 크라머, 한스 루돌프 하우스 피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
DK0577040T3 (da) 1992-07-02 1998-02-02 Hoechst Ag Fremgangsmåde til fremstilling af (3R,5S)6-hydroxy-3,,5-O-isopropyliden-3,5-dihydroxyhexansyre-tert.-butylester
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
WO1997049681A1 (en) 1996-06-24 1997-12-31 Astra Aktiebolag (Publ) Polymorphic compounds
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
CA2320163C (en) 1998-12-10 2008-09-23 Kaneka Corporation Process for producing simvastatin
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001022962A1 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
PT1235799E (pt) 1999-11-17 2005-05-31 Teva Pharma Forma polimorfica de atorvastatina-calcio
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
JP3737801B2 (ja) 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
AU3289102A (en) 2000-11-16 2002-06-11 Teva Pharma Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (es) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
JP2004536813A (ja) 2001-06-06 2004-12-09 ブリストル−マイヤーズ　スクイブ　カンパニー キラルジオールスルホンおよびジヒドロキシ酸ＨＭＧＣｏＡレダクタ−ゼ阻害剤
WO2003006439A1 (en) * 2001-07-13 2003-01-23 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
TR200302281T2 (tr) * 2001-08-16 2004-09-21 Teva Pharmaceutical Industries Ltd. Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
CN1545502A (zh) 2001-08-22 2004-11-10 �������⻯ѧƷ�ع����޹�˾ 吲哚衍生物的制备方法
EP1465667A4 (en) 2001-09-24 2007-06-27 Merck & Co Inc SCREENING AND SELECTION PROCEDURE FOR STATIN COMBINATIONS
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) * 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
BR0311195A (pt) 2002-05-21 2005-02-22 Ranbaxy Lab Ltd Processo de preparação de rosuvastatina
EP1375493A1 (en) * 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
HUP0500851A3 (en) 2002-12-10 2008-02-28 Ranbaxy Lab Ltd Process for the preparation of rosuvastatin
DK1578731T3 (da) * 2002-12-16 2010-02-15 Astrazeneca Uk Ltd Fremgangsmåde til fremstilling af pyrimidinforbindelser
BRPI0409292A (pt) 2003-04-11 2006-04-11 Lek Pharmaceuticals processo para a preparação de sal de cálcio amorfo de atorvastatina
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
AU2003247327A1 (en) 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2657076A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ES2364143T3 (es) 2003-12-02 2011-08-25 Teva Pharmaceutical Industries Ltd. Estandar de referencia para caracterización de rosuvastatina.
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
CA2550742A1 (en) 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1709008A1 (en) 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
WO2005077917A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
JP2008528542A (ja) 2005-01-31 2008-07-31 チバ ホールディング インコーポレーテッド ロスバスタチンカルシウム塩の結晶形
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
JP4614238B2 (ja) * 2006-07-14 2011-01-19 ルネサスエレクトロニクス株式会社 Ｒｆ電力増幅装置
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
IS8478A (is) 2006-05-22
JP2007509119A (ja) 2007-04-12
AU2004285750A1 (en) 2005-05-12
ES2404693T3 (es) 2013-05-28
CN101654453A (zh) 2010-02-24
CA2543358A1 (en) 2005-05-12
EP1682536B1 (en) 2013-02-27
AU2004285750B2 (en) 2008-03-13
IL175086A0 (en) 2006-08-20
US9371291B2 (en) 2016-06-21
NZ547094A (en) 2009-05-31
SA04250425B1 (ar) 2009-08-11
HK1092462A1 (en) 2007-02-09
ZA200603173B (en) 2007-07-25
RU2006117337A (ru) 2007-12-10
RU2372349C2 (ru) 2009-11-10
NO20062263L (no) 2006-05-19
CN1898233B (zh) 2012-06-13
TWI344957B (en) 2011-07-11
PL1682536T3 (pl) 2013-08-30
CN101654453B (zh) 2012-07-04
CY1114145T1 (el) 2016-07-27
SI1682536T1 (sl) 2013-07-31
EP2272842A1 (en) 2011-01-12
JP2008024712A (ja) 2008-02-07
GB0324791D0 (en) 2003-11-26
TW200523256A (en) 2005-07-16
US20070255060A1 (en) 2007-11-01
MY146002A (en) 2012-06-15
UA83076C2 (en) 2008-06-10
US20110301348A1 (en) 2011-12-08
BRPI0415681A (pt) 2006-12-19
CN1898233A (zh) 2007-01-17
KR20060132829A (ko) 2006-12-22
JP2008044948A (ja) 2008-02-28
EP1682536A1 (en) 2006-07-26
DK1682536T3 (da) 2013-05-06
AR046191A1 (es) 2005-11-30
PT1682536E (pt) 2013-05-06
WO2005042522A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
UY28577A1 (es) Proceso químico e intermedios
DK1144389T3 (da) Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt
CY1109173T1 (el) Κρυσταλλικη μορφη του δις [(ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3r,5s)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] αλατος ασβεστιου
DK1263739T3 (da) Krystallinske salte af 7-[4-(4-fluorphenyl)-6-isopropyl-2-methyl(methylsulfonyl) aminopyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoinsyre
BRPI0410922A (pt) processo para a formação de um composto, e, composto
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
BRPI0516905A (pt) processo para a preparação de um derivado n-[2-(2-piridinil)etil]carboxamida e compostos
AR064027A1 (es) Proceso quimico para preparar rosuvastatina y su sal de sodio y/o calcio
DE60130771D1 (de) Substituierte heterocyclische amide
RU2009124489A (ru) Соединения бензоилпиразола, способ их получения и гербициды, содержащие их
NO20061324L (no) Polymorfe former av en kjent antihyperlinemisk forbindelse
PE20061057A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE HMG CoA REDUCTASA
PE20060184A1 (es) Derivados de imidazoles como inhibidores de la sintesis del colesterol
DK1723140T3 (da) Fremgangsmåde til fremstilling af tryptase-inhibitorer
ATE485277T1 (de) Verfahren zur herstellung eines 3,5-dihydroxy-6- heptenoats
AR051987A1 (es) Compuestos 3-alquil-1,2-dicloro-4-fluorobenceno y proceso para su preparacion
TH73095A (th) กระบวนการทางเคมีและอินเทอร์มีเดียต
EA200200563A1 (ru) Новые соединения инденоиндолона, способ их получения и фармацевтические композиции, их содержащие

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150601